THALES
5.8.2021 04:02:05 CEST | Business Wire | Press release
Thales and Dah Chong Hong – Dragonair Airport GSE Service Ltd. (DAS) announced that they have been selected by the Civil Aviation Department (CAD) of the Hong Kong Special Administrative Region Government through global open tender exercise to deploy the new Instrument Landing System (ILS) and to support the Three-runway System (3RS) expansion project at the Hong Kong International Airport (HKIA). This leading solution will largely help HKIA further improve the capacity and efficiency of aircraft landing while maintaining the highest standard of flight safety.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005024/en/
The six sets of new ILS to be installed at the HKIA under 3RS will make use of Thales state-of-the-art technologies. The new ultra-wide aperture localizer array with 32-element localizer antenna will provide highly accurate guidance signals to aircraft approaching and landing on the runway in all weather conditions, day and night, allowing the safest and the most efficient aircraft landing at the HKIA while requiring less equipment safeguarding area.
The new ILS will also support selected runways with Category III operations including Low Visibility Operations (LVO) under foggy/heavy rain conditions. The whole Thales solution has already been deployed at various major international airports, such as Istanbul New Airport and Ankara Esenboga Airport in Turkey as well as Paris Charles De Gaulle Airport in France.
In Hong Kong, Thales has been supporting HKIA with superior products and technologies over the past 20 years as it has grown and become one of the busiest regional and international aviation hub. With HKIA stepping up its capacity to cater for the increasing demand of air traffic growth, Thales, as one of the most trusted partners of CAD, will once again contribute to “one of the largest infrastructure projects in Hong Kong’s history”.
“We are proud to have been selected by the Civil Aviation Department under global open tender as the supplier of new ILS for the HKIA, which is one of the key systems with proven international reference and reliability performance to support operations on the runway. This new selection strengthens our position as a proven airspace solutions provider in Asia and makes HKIA a world reference in terms of navigation aids equipped airport. I am sure the knowledge and experience that Thales is bringing to the project will ensure smooth and reliable operations at the HKIA during aircraft landing.” Mr. Kais MNIF, Navigation and Non-radar Surveillance Global Business Director, Thales.
“We are also delighted to work together with Thales as the local partner for the ILS solution. This project will leverage the strength and expertise of both companies to jointly deliver a world-class critical air navigation service equipment to CAD at the Hong Kong International Airport.” Angel Cheung, General Manager, Dah Chong Hong – Dragonair Airport GSE Service Ltd.
DAS is responsible for the project liaison and coordination with various stakeholders, overall logistic support, and on-site installation of this advanced ILS project. Thales together with DAS, commit to ensuring on-time and satisfying delivery of the solution to the CAD. Both companies have cooperated on several aviation projects to cater for future aviation traffic growth in the region, which will definitely further accelerate the on-going development in the Guangdong-Hong Kong-Macau Greater Bay Area.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
About Thales in China
Thales provides innovative solutions for the infrastructure that forms the backbone of China’s growth. The Group has been present in China for more than 40 years and is the trusted partner for the Chinese aviation and urban rail transportation industries. In the meanwhile, from secure software to biometrics and encryption, Thales has successfully applied its advanced technology to mobile communication, banking, IoT and software monetization etc. Thales has 3 JVs and employs 2,100 people with offices located in 7 cities in China. Thales established R&D centers and Innovation Hubs in Beijing, Dalian and Hong Kong to provide innovative solutions for both China and international market.
About Dah Chong Hong – Dragonair Airport GSE Service Ltd.
Dah Chong Hong –Dragonair Airport GSE Service Ltd. (“DAS”), a subsidary of Dah Chong Hong Holdings established in 1996, is an aviation support service provider with operations in Hong Kong and mainland China. DAS provides a wide array of professional services for the global aviation industry including supply, development and implementation of airport special system as well as design, supply, maintenance, leasing and fleet management of aviation and airport ground support equipment.
About Dah Chong Hong Holdings
Dah Chong Hong Holdings, an indirect wholly owned subsidiary of CITIC Limited (stock code: 0267.HK), is an integrated trading and distribution company operating in Asia, supported by an extensive logistics network. DCH is a leading distributor and dealer of motor vehicles in Greater China as well as a provider of a full range of associated services. DCH’s consumer business comprises the manufacture, retail and distribution of food, healthcare, electrical appliances, beauty and lifestyle products. DCH employs over 16,500 staff with operations in 12 Asian markets.
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom